Successful use of hydroxymethylquinoxaline dioxide in complex antimicrobial therapy in patients with fulminant infectious complications in induced hematopoesis aplasia by gram-negative agents

Relevance. Infectious septic complications caused by polyresistant gram-negative micro-organisms are a pressing issue in the treatment of patients after polychemotherapy (PCT) and hematopoietic stem cell transplantation at the high risk of the fulminant current and high lethality against the background of hematopoesis aplasia. One of the therapeutic strategies of antimicrobial treatment is the systematic use of 0.5 % hydroxymethylquinoxaline dioxide (dioxidine) solution in the complex antibacterial therapy of patients with severe infectious-septic complications. The preparation has a bactericidal type of action, a wide spectrum of antibacterial activity. Experience in adult clinical practice has demonstrated the effectiveness of dioxidine in the treatment of the most severe forms of aerobic and anaerobic infection. Strict dose enforcement and injection technique to avoid the appearance of side effects. Data on the intravenous use of dioxin in children are presented in a limited number of scientific literature.

The aim of the study was to demonstrate the efficacy of systemic use of hydroxymethylquinoxaline dioxide (0.5 % dioxidine solution) in children with infectious complications progressing against the background of aplasia of hematopoiesis caused by multidrug-resistant pathogens Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae, Stenotrophomonas maltophilia.

Materials and methods. 16 patients with a verified gram-negative infection were prescribed 0.5 % hydroxymethylquinoxaline dioxide solution as part of a combination antimicrobial therapy were included in the retrospective study. The median age of patients was 5 years (6 months – 16 years), 11 (69 %) were boys and 5 (31 %) girls.

All children included in the study has infectious-septic complications at the PCT-induced hematopoietic aplasia, obtained according to the protocols of the main disease: severe combined immune deficiency (n = 2), idiopathic aplastic anaemia (n = 3), solid tumor (n = 2), acute myeloblastic leukemia (n = 7), acute lymphoblastic leukemia (n = 2). The main criterion for adding to the study was the existence at the least one site with a verified gram-negative infection (Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter cloacae, Stenotrophomonas maltophilia): bacteriemia (n = 11), oral mucosa (n = 6), ulcerative necrotic damage of perineum (n = 6), enterocolite (n = 6), infectionseptic compartments in the subcutaneous fat (n = 4), pleuropneumonia (n = 4), abscesses and inflammatory infiltration of the liver, spleen, pancreas, kidneys, lymph nodes (n = 1), infection of soft tissues in the area of the ventricular bypass with inflammatory changes of the brain membranes (n = 1).

All patients received 0.5 % of the solution of dioxin by injection according of vital importance, as they had pathogens with confirmed laboratory resistance or clinical progression of the infectious process against the background of combined antibacterial therapy.

Discussion. There is a complete control of fulminant developing infectious-septic processes caused by polyresistant micro-organisms against the background of hydroxymethylquinoxaline dioxide therapy in all 16 patients. The eradication of the pathogen, according to the microbiological study, has been confirmed in almost all observed patients, the efficacy of the drug has been preserved throughout the period of treatment, and the resistance of micro-organisms has not been observed. Strict adherence to the dosing and infusion technique of hydroxymethylquinoxaline dioxide has helped to achieve the full resolution of the infection process in all children without side-effects.

Conclusion. On the basis of the experience presented, in immunocomputed patients of young age, 0.5 % dioxidine solution can be used as a necessary reserve preparation for the treatment of the most severe forms of infections of different localization, caused by polyresistant strains of gram-negative micro-organisms.

1. Nikifirova G.N., Svistushkin V.M., Dedova M.G. Possibilities of local treatment of infectious and infl ammatory diseases of LOR organs. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2015;6:346–9. (In Russ.).

2. Padeyskaya E.N. Antibacterial preparation of dioxidine: features of biological action and importance in the treatment of various forms of purulent infection. Infektsii i antimikrobnaya terapiya = Infections and Antimicrobial Therapy 2001;3(5):150–5. (In Russ.).

3. Padeyskaya E.N. Antimicrobial drugs among derivatives of sulfanylamide, diaminopyrimidine, 5-nitroimidazola di-N-oxychinoxalin. Russkiy meditsinskiy zhurnal = Russian Medical Journal 1997;21:1–6. (In Russ.).

4. Popov D.A., Anuchkina N.M., Terentiev A.A., Kostuk G.V., Blatun L.A., Rusanova E.V., Alexandrova I.A., Pchakadze T.Ya., Bogomolova N.S., Terekhova L.P. Dioxidine: antimicrobial activity and prospects for clinical use at the current stage. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy 2013;58:3–4. (In Russ.).

5. Durnev A.D., Dubrovskaya O.Yu., Nigarova E.A., Seredenin S.B. The role of free oxygen radicals in the mutagenic action mechanism of dioxidin. Khimiko-farmatsevticheskiy zhurnal = Chemical and Pharmaceutical Journal 1989;23(11):1289–91. (In Russ.).

6. Suter W., Russelet A., Knüsel F. Mode of Action of Quindoxin and Substituted quinoxaline-di-N-oxides on Escherichia Coli. Antimicrob Agents Chemother 1978;13(5):770–83. doi: 10.1128/aac.13.5.770.

7. A report on the results of the evaluation of the activity in vitro of an antimicrobial preparation of dioxidine on the bases of the National Centre of Medicine of A.N. Bakulev, with the participation of the Research Institute of Neurosurgery named after Acad. N.N. Burdenko, Research Institute of Surgery named after A.V. Vishnevsky, CITO named after N.N. Priorov, MONIKI named after M.F. Vladimirskiy. (In Russ.).

8. Padeiskaya E.N., Shipilova L.D., Budanova L.I. Pharmacokinetic dioxidine, penetration of the drug into organs and tissues at a single and repeated injection. Khimiko-farmatsevticheskiy zhurnal = Chemical and Pharmaceutical Journal 1983;6:667–71. (In Russ.).

9. Mezentseva A.V., Olkhova L.V., Machneva E.B., Konstantinova V.V., Burya A.E., Nikolaeva Yu.A., Filina O.A., Pristanskova E.A., Purbueva B.B., Fink O.S., Antoshin M.M., Skorobogatova E.V. Treatment of fulminant infectious complications caused by gram-negative agents in patients with aplasia-induced hemorrhaging. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatria. Journal named after G.N. Speransky 2020;99(4):252–7. (In Russ.). doi: 10.24110/0031-403X-2020-99-4-252-257.